ArticleFrontiers in oncology2025

Acquired ROS1 fusion and iruplinalkib response in advanced NSCLC after multiple lines of systematic therapy: a case report.

Jiarui Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.